author-photo

Suresh S. Ramalingam

Emory University Hospital

13

Papers

113

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (36)
Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Utilization patterns of immune checkpoint inhibitors (ICI) for non-small cell lung cancer (NSCLC) within the veterans health administration (VHA).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (19)
High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)